HMGB1 and B-cell chronic lymphocytic leukemia: SpiD3 (0.5–2 μM) treatment significantly induced extracellular ATP release from OSU-CLL cells as the treatment duration approached 24 h (Figure 3C); the magnitude of HMGB1 released was greatest from OSU-CLL cells treated with 2 μM SpiD3 at this same timepoint (Figure 3C).